An interventional study of Implemented procedure in Infection of Skin and/or Subcutaneous Tissue, sponsored by Federico II University. Withdrawn at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-12-31.
Sponsored by Federico II University · Not applicable, Interventional, and Treatment
The general objective of the study is to assess whether the implementation of the antibiotic essay with the Breakpoint/MIC ratio and data on penetration of the antibiotic in the site of infection may improve the outcome of infections compared to using only the standard procedures.
86 studies on the registry are indexed under Skin Diseases, Infectious; 4 are open to participants now.
Browse Skin Diseases, Infectious studies →Federico II University is the lead sponsor of 356 studies on the registry; 60 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Antibiotic prescription following in vitro sensitivity test according to each surgeon's will.
Prescription following in vitro sensitivity test implemented with MIC/Breakpoint ratio and penetration of antibiotic in the site of infection, according to each surgeon's will.
Behavioral: Implemented procedure
Prescription following in vitro sensitivity test implemented with MIC/Breakpoint ratio and penetration of antibiotic in the site of infection.
Also known as: MIC/Breakpoint ratio and tissue penetration for available antibiotics e.g., - Semisynthetic Penicillins, - Cephalosporins, - Linezolid, - Vancomycin, - Daptomycin, - Teicoplanin, - Tigecycline
Complete recovery rate from infection
Complete resolution of fever, leukocytosis, and any local signs of infection
Time frame: At the end of treatment (an expected average of 10 days)
Time to recovery from infection.
Days to recovery completely from infection.
Time frame: At the end of treatment (an expected average of 10 days)
Partial response
Improvement of fever, leukocytosis, and any local signs of infection
Time frame: At the end of treatment (an expected average of 10 days)
Rate of non responders
Treatment failure, relapse and death. Failure is defined as no improvement or even worsening of the signs and symptoms of infection. Relapse is defined as the resumption of infection with the same organism at any body part within one month after completion of treatment
Time frame: At the end of treatment (an expected average of 10 days)
This study is withdrawn, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Federico II University